Therapeutic effects of irbesartan combined amiodarone on heart failure patients with atrial fibrillation and its influence on cardiac function ,plasma levels of Ang‐Ⅱ,NE and BNP／ / 心血管康复医学杂志

ABSTRACT

To study therapeutic effects of irbesartan combined amiodarone on heart failure (HF) patients with atrial fibrillation (AF) and its influence on cardiac function ,plasma levels of Ang‐Ⅱ,NE and BNP .Methods:A total of 98 HF patients with AF treated in our hospital from Sep 2016 to Sep 2017 were randomly divided into ami‐odarone group (received amiodarone based on routine treatment ) and combined treatment group (received irbesar‐ tan based on amiodarone group).Both group were treated for six months .HR ,BP ,cardiac function indexes ,plas‐ma levels of Ang‐Ⅱ,NE and BNP before and after treatment ,and incidence of adverse reactions were observed and compared between two groups .Results: Compared with before treatment ,after treatment ,there were significant reductions in HR ,BP ,LVEDd ,LVESd ,plasma levels of Ang‐Ⅱ,NE and BNP ,and significant rise in LVEF in two groups , P＜0. 05 or ＜0. 01. Compared with amiodarone group ,after treatment ,there were significant reduc‐tions in HR [(95. 6 ± 13.7) beats／min vs .(81. 4 ± 11. 8) beats／min] ,BP [(145. 7 ± 20.6)／(89.1 ± 11.4) mmHg vs.(132.3 ± 17.5)／(81.3 ± 10.2) mmHg] ,LVEDd [ (58.3 ± 5.2) mm vs.(53.2 ± 4.6) mm] ,LVESd [ (44. 2 ± 5. 1) mm vs.(38.1 ± 4.9) mm] ,plasma levels of Ang‐Ⅱ[(113.27 ± 10.14) pg／ml vs.(98.67 ± 8. 79) pg／ml] , NE [(1.90 ± 0. 31) pg／ml vs.(1.74 ± 0. 28) pg／ml] and BNP [(282.18 ± 54.16) pg／ml vs.(214. 36 ± 41. 25) pg／ml] ,and significant rise in LVEF [(39.8 ± 4.1)% vs.(48.6 ± 5. 5)%] in irbesartan group ,P＜0.01 all.There was no significant difference in incidence rate of adverse reactions during treatment between two groups , P＝ 0.712. Conclusion:Irbesartan combined amiodarone can effectively improve cardiac function ,reduce HR ,BP ,plasma lev‐els of Ang‐Ⅱ,NE and BNP with good safety in HF patients with AF .